Kurome Therapeutics Closes $15 Million Series A Financing To Develop Targeted Kinase Inhibitors For Treatment Of Hematopoietic Cancers
Kurome Therapeutics Closes $15 Million Series A Financing To Develop Targeted Kinase Inhibitors For Treatment Of Hematopoietic Cancers
06/10/21, 11:09 AM
Location
cincinnatiMoney raised
$15 million
Round Type
series a
Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing. The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors.
Company Info
Location
cincinnati, ohio, united states
Additional Info
Kurome® Therapeutics is a preclinical stage company developing novel therapies that subvert cancer’s ability to evade treatment. Founded on research at Cincinnati Children’s Hospital Medical Center in collaboration with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), Kurome is developing a series of combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that have co-opted IRAK1/4-mediated immune signaling pathways to survive.